Profile data is unavailable for this security.
About the company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
- Revenue in USD (TTM)7.99m
- Net income in USD-40.58m
- Incorporated2014
- Employees41.00
- LocationCue Biopharma Inc40 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 949-2680
- Fax+1 (302) 655-5049
- Websitehttps://www.cuebiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences Inc | 51.14m | -21.99m | 48.12m | 107.00 | -- | 0.9279 | -- | 0.941 | -2.01 | -2.01 | 6.47 | 4.68 | 0.3309 | -- | 58.35 | 473,527.80 | -14.22 | -26.22 | -16.69 | -33.68 | -- | -- | -42.99 | -87.80 | -- | -- | 0.3117 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| vTv Therapeutics Inc | 17.00k | -18.69m | 48.14m | 23.00 | -- | 6.07 | -- | 2,831.89 | -3.01 | -3.01 | 0.0027 | 2.48 | 0.0004 | -- | -- | 739.13 | -53.13 | -96.30 | -68.57 | -- | -- | -- | -134,723.50 | -775.06 | -- | -- | 0.00 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Pelthos Therapeutics Inc | 0.00 | -7.36m | 49.03m | 4.00 | -- | -- | -- | -- | -12.40 | -12.40 | 0.00 | -6.79 | 0.00 | -- | -- | 0.00 | -297.84 | -- | -- | -- | -- | -- | -- | -- | -- | -25.62 | -- | -- | -- | -- | -7.78 | -- | -- | -- |
| CervoMed Inc | 9.31m | -18.67m | 49.17m | 15.00 | -- | 1.42 | -- | 5.28 | -2.14 | -2.14 | 1.07 | 3.98 | 0.3997 | -- | 11.43 | 620,547.30 | -80.17 | -54.89 | -93.42 | -60.99 | -- | -- | -200.58 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -55.21m | 49.35m | 1.00 | -- | 2.73 | -- | -- | -168.14 | -168.14 | 0.00 | 1.56 | 0.00 | -- | -- | -- | -489.35 | -- | -759.66 | -- | -- | -- | -- | -- | -- | -106.70 | 0.0644 | -- | -- | -- | 35.61 | -- | -- | -- |
| Renovaro Inc | 0.00 | -67.01m | 49.73m | 25.00 | -- | 0.5308 | -- | -- | -0.4327 | -0.4327 | 0.00 | 0.5443 | 0.00 | -- | -- | 0.00 | -40.61 | -39.86 | -47.81 | -42.11 | -- | -- | -- | -- | -- | -10.46 | 0.0634 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| Gain Therapeutics Inc | 0.00 | -20.93m | 49.95m | 23.00 | -- | 8.41 | -- | -- | -0.8868 | -0.8868 | 0.00 | 0.2011 | 0.00 | -- | -- | 0.00 | -159.74 | -79.58 | -258.86 | -95.32 | -- | -- | -- | -19,975.78 | -- | -- | 0.0689 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Adicet Bio Inc | 0.00 | -117.32m | 50.20m | 152.00 | -- | 0.311 | -- | -- | -1.29 | -1.29 | 0.00 | 1.95 | 0.00 | -- | -- | 0.00 | -48.44 | -36.24 | -52.09 | -39.41 | -- | -- | -- | -813.80 | -- | -- | 0.00 | -- | -- | -- | 17.90 | -- | 32.77 | -- |
| OS Therapies Inc | 0.00 | -13.27m | 51.42m | 4.00 | -- | -- | -- | -- | -0.7949 | -0.7949 | 0.00 | 0.0288 | 0.00 | -- | -- | 0.00 | -426.54 | -- | -- | -- | -- | -- | -- | -- | -- | -9.14 | 0.00 | -- | -- | -- | -37.51 | -- | -- | -- |
| ABVC Biopharma Inc | 508.39k | -1.81m | 52.16m | 16.00 | -- | 8.85 | -- | 102.61 | -0.1434 | -0.1434 | 0.0392 | 0.3514 | 0.0347 | -- | 0.7076 | 31,774.38 | -15.15 | -105.17 | -32.38 | -217.00 | 99.90 | 75.19 | -437.11 | -2,124.21 | 0.2166 | -2.44 | 0.1706 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| Cue Biopharma Inc | 7.99m | -40.58m | 52.38m | 41.00 | -- | 6.53 | -- | 6.56 | -0.6644 | -0.6644 | 0.1278 | 0.1064 | 0.2097 | -- | 11.42 | 194,902.40 | -106.51 | -60.20 | -190.46 | -73.56 | -- | -- | -507.87 | -683.99 | -- | -- | 0.339 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| Avalo Therapeutics Inc | 441.00k | -21.10m | 53.71m | 23.00 | 0.2264 | 0.438 | 0.7329 | 121.78 | 21.91 | 21.91 | 0.0496 | 11.32 | 0.0034 | -- | -- | 19,173.91 | 55.68 | -94.60 | 356.71 | -128.31 | 164.85 | 81.11 | 16,556.01 | -790.66 | -- | -- | 0.00 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -3.33m | 54.62m | 4.00 | -- | 17.82 | -- | -- | -0.104 | -0.104 | 0.00 | 0.0926 | -- | -- | -- | 0.00 | -- | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -20.74 | 0.0456 | -- | -- | -- | 49.00 | -- | -- | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -51.87m | 55.35m | 123.00 | -- | 2.17 | -- | -- | -1.62 | -1.62 | 0.00 | 0.6907 | 0.00 | -- | -- | 0.00 | -51.49 | -- | -97.48 | -- | -- | -- | -- | -- | -- | -27.17 | 0.5165 | -- | -- | -- | 52.51 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -19.70m | 56.07m | 13.00 | -- | 11.07 | -- | -- | -0.8202 | -0.8202 | 0.00 | 0.167 | 0.00 | -- | -- | 0.00 | -191.49 | -208.29 | -371.24 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
Data as of Jul 03 2025. Currency figures normalised to Cue Biopharma Inc's reporting currency: US Dollar USD
17.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bleichroeder LPas of 31 Mar 2025 | 5.00m | 7.89% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 2.30m | 3.64% |
| Park City Capital LLCas of 05 Jun 2024 | 1.00m | 1.58% |
| Geode Capital Management LLCas of 31 Mar 2025 | 693.89k | 1.10% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 559.80k | 0.88% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Mar 2025 | 478.50k | 0.76% |
| Sigma Planning Corp.as of 31 Mar 2025 | 326.26k | 0.52% |
| Bank of America, NA (Private Banking)as of 31 Mar 2025 | 324.34k | 0.51% |
| Advisory Research, Inc.as of 31 Mar 2025 | 257.23k | 0.41% |
| 1919 Investment Counsel LLCas of 31 Mar 2025 | 196.56k | 0.31% |
More ▼
Data from 05 Jun 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
